Predictors of Cladribine Effectiveness and Safety in Multiple Sclerosis: A Real-World, Multicenter, 2-Year Follow-Up Study

INTRODUCTION: Cladribine administration has been approved for the treatment of relapsing–remitting multiple sclerosis (MS) in 2017; thus, data on cladribine in a real-world setting are still emerging. METHODS: We report on cladribine effectiveness, safety profile, and treatment response predictors i...

Descripción completa

Detalles Bibliográficos
Autores principales: Petracca, Maria, Ruggieri, Serena, Barbuti, Elena, Ianniello, Antonio, Fantozzi, Roberta, Maniscalco, Giorgia Teresa, Andreone, Vincenzo, Landi, Doriana, Marfia, Girolama Alessandra, Di Gregorio, Maria, Iodice, Rosa, Sinisi, Leonardo, Maida, Elisabetta, Missione, Rosanna, Coppola, Cinzia, Bonavita, Simona, Borriello, Giovanna, Centonze, Diego, Lus, Giacomo, Pozzilli, Carlo, Signoriello, Elisabetta
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Healthcare 2022
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9338179/
https://www.ncbi.nlm.nih.gov/pubmed/35653061
http://dx.doi.org/10.1007/s40120-022-00364-6

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9338179/
https://www.ncbi.nlm.nih.gov/pubmed/35653061
http://dx.doi.org/10.1007/s40120-022-00364-6

Ejemplares similares